

(SD2022-222) Optimized CAG repeat-targeting CRISPR/cas13d designs

Tech ID: 33694 / UC Case 2021-Z08-1

ABSTRACT

Reseachers from UC San Diego demonstrated a proof of principle for a CAGEX RNA-targeting CRISPR–Cas13d system as a potential allele-sensitive therapeutic approach for HD, a strategy with broad implications for the treatment of other neurodegenerative disorders.

TECHNOLOGY DESCRIPTION

Researchers from UC San Diego leveraged the advantageous compact nature of *Ruminococcus flavefaciens* XPD3002 (Rfx) CRISPR/Cas13d and engineered a CRISPR/Cas13d-based gene therapy vector packaged into a single vector in both lentiviral and adeno-associated viral delivery vehicles, that silences mutant toxic CAG-expanded (CAGEX) RNA in both human patient iPSC models and an established mouse model of HD.

APPLICATIONS

- 1) Research tool. To target, locate, and track intracellular or extracellular CAG expansion-containing RNA transcripts in fixed or living cells and/or in vivo.
- 2) Biomarker. Can serve as a pharmacodynamic biomarker to assess efficacy of potential therapies that target CAG expansions including small molecules or natural/synthetic compounds and/or any DNA or RNA-targeting gene therapy approach.
- 3) Therapeutic for disease. To target and destroy disease-causing RNA transcripts harboring toxic CAG expansions including those that cause HD.

ADVANTAGES

CONTACT

Skip Cynar
scynar@ucsd.edu
tel: 858-822-2672.



OTHER INFORMATION

KEYWORDS

gene therapy, HD therapeutics,
Huntington's disease, RNA-targeting
CRISPR

CATEGORIZED AS

- ▶ **Biotechnology**
 - ▶ Health
- ▶ **Medical**
 - ▶ Disease: Central Nervous System
 - ▶ Gene Therapy
 - ▶ Therapeutics

RELATED CASES

2021-Z08-1




Fig. 1 | Development of an RNA-targeting Cas13d-based gene therapy approach for HD. **a**, Treatment scheme of our single gene therapy that expresses Cas13d and a gRNA designed to eliminate CAG-expanded HTT *HTT* RNA in both human striatal neuronal cultures derived from patient iPSCs and in the striatum of an established mouse model of HD, *zQ175/+*. **b**, Diagram of a series of CAG-expanded, RNA-targeting vectors that consists of (1) Cas13d tagged with an HA epitope and (2) one of three U6 promoter-driven Rfx CRISPR-Cas13d gRNAs (denoted as CAG^{EX} gRNA 1-3). **c**, Western blot analysis of polyQ protein from protein lysates isolated from HEK293 cells transfected with a CAG¹⁰⁵ repeat

plasmid and each candidate Cas13d vector. **d,e**, RNA dot blot analysis (**d**) and quantification (**e**) of CAG-expanded RNA within HEK293 cells transfected with a CAG¹⁰⁵ repeat plasmid along with a nontargeting control (NT) or CAG^{EX}-2 vector (one-way ANOVA, Tukey post hoc test, *****P* < 0.0001; *n* = 1 technical replicates, *n* = 3 biological replicates). **f,g**, RNA dot blot analysis (**f**) and quantification (**g**) of CUG-expanded RNA within HEK293 cells transfected with a CUG¹⁰⁶ repeat plasmid along with a NT or CAG^{EX}-2 vector (one-way ANOVA, Tukey post hoc test, *n* = 3 technical replicates, *n* = 3 biological replicates).

STATE OF DEVELOPMENT

The UCSD researchers have collected extensive preclinical data in two established models of HD for a new gene therapy strategy that effectively eliminates CAG-expanded pre-mRNA with the use of RNA-targeting CRISPR/Cas13d technology. Specifically, they engineered a potent gene therapy vector that encases *Ruminococcus flavefaciens* Cas13d, an RNA-targeting enzyme only 2.4 kb in size, and a CAG-expansion RNA-targeting gRNA in a single viral delivery vehicle. They utilized multiple established preclinical models of HD including the Q175/+ mouse model which harbors one human allele of HTT with 175 CAG repeats in exon 1, and a series HD patient iPSC-derived striatal neurons to show both efficacy and safety of the new gene therapy approach both in vivo and in a humanized preclinical model.

Further details are in the manuscript.

INTELLECTUAL PROPERTY INFO

University is securing US patent rights, see:

<https://patents.google.com/patent/WO2023154843A2/en?q=US2023%2f062352>

Please contact UCSD if you are interested in licensing this technology for commercial development.

RELATED MATERIALS

► Morelli KH, Wu Q, Gosztyla ML, Liu H, Yao M, Zhang C, Chen J, Marina RJ, Lee K, Jones KL, Huang MY, Li A, Smith-Geater C, Thompson LM, Duan W, Yeo GW. An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models. *Nat Neurosci.* 2023 Jan;26(1):27-38 - 12/12/2022

University of California, San Diego
Office of Innovation and Commercialization
9500 Gilman Drive, MC 0910, ,
La Jolla, CA 92093-0910

Tel: 858.534.5815
innovation@ucsd.edu
<https://innovation.ucsd.edu>
Fax: 858.534.7345

© 2024, The Regents of the
University of California
[Terms of use](#)
[Privacy Notice](#)